anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

200,821-200,880 of 319,975

filter-aware
09
AppHarvest | Results Presentation Deck | 13 slidesAppHarvest | Results Presentation Deck | 13 slides · AppHarvest
Conference presentation Investor relations 1 hit
10
Includes non-GAAP financial measure disclaimer.AppHarvest | Results Presentation Deck | 13 slides · AppHarvest
Conference presentation Investor relations 1 hit
11
Uses a timeline framework with illustrative icons for each year.AppHarvest | Results Presentation Deck | 13 slides · AppHarvest
Conference presentation Investor relations 1 hit
12
The slide provides a standard non-GAAP financial reconciliation for AppHarvest.AppHarvest | Results Presentation Deck | 13 slides · AppHarvest
Conference presentation Investor relations 1 hit
13
This is a branding/filler slide used in an earnings presentation.AppHarvest | Results Presentation Deck | 13 slides · AppHarvest
Conference presentation Investor relations 1 hit
01
Slide 1
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
02
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
03
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
04
Includes a legend for technical acronyms at the bottom.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
05
The chart uses a Gantt-style visualization to represent drug development stages.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Problem1 hit
07
Uses a geographic map and a nested circle diagram to illustrate the treatment gap.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a process-oriented diagram to show how three distinct mechanisms of action (MOAs) combine to lead to a clinical outcome.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
Includes a schematic of the GalNAc-linker-RNAi construct and a bar chart illustrating the suppression of various HBV transcripts.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide outlines the study structure for a clinical trial, categorizing cohorts by dosage and patient status (HBV DNA +/-).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
11
Data presented at EASL 2022 and AASLD 2022.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
12
The slide displays longitudinal data for cohorts E, F, I, J, G, and K, highlighting individual patient responses and key clinical outcomes.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide displays 8 individual patient case studies (Pt 46, 51, 52, 53, 56, 58, 59, 60, 61).Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
14
Data presented at EASL 2022. Shows longitudinal patient data for patients 42, 43, and 48.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
15
The slide uses a bulleted list with custom circular icons to present clinical safety findings.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
16
Data presented at AASLD 2022.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
17
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
18
The slide outlines a clinical trial design with two main arms involving AB-729, VTP-300, and optional Nivolumab.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
19
The slide details a specific licensing deal, including financial terms and partner background.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
20
The slide uses a three-column layout to explain the scientific basis and benefits of the drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
Includes IC50 value and IFN-y fold increase data from patient samples.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The slide uses a three-column layout to highlight the core benefits of the product.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
Includes both longitudinal efficacy data (line chart) and pharmacokinetic data (bar charts) comparing plasma vs liver concentrations.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
25
The slide maps the viral genome to specific drug targets and highlights partnerships with X-Chem and Proteros.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
26
The slide highlights key therapeutic advantages of the candidate drug.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
27
The slide uses a table to present a timeline of clinical milestones.Arbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
28
Arbutus Biopharma | Investor Presentation Deck | 28 slidesArbutus Biopharma | Investor Presentation Deck | 28 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
01
Slide 1
argenx SE | Investor Presentation Deck | 22 slidesargenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
02
argenx SE | Investor Presentation Deck | 22 slidesargenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
03
The slide uses a thematic background with a network/molecular graphic overlay.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
04
The slide uses a circular graphic element to emphasize the 'revolution' in autoimmunity.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
05
argenx SE | Investor Presentation Deck | 22 slidesargenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
06
The slide uses a hub-and-spoke style layout with a central mission statement and four surrounding strategic pillars.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
07
The slide uses a waterfall-style bar chart to show quarterly revenue progression, though it is technically a standard bar chart.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
08
The slide uses a combination of clinical trial charts and a logo-grid of scientific journals to establish credibility.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
09
The slide uses a circular cluster diagram to represent four strategic pillars.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Why Now1 hit
10
The slide uses a hub-and-spoke style diagram to categorize commercial growth drivers.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
11
The slide uses a hub-and-spoke visual metaphor to link the 'Pioneer FcRn class of medicines' to a list of specific autoantibodies.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
12
The slide uses a pyramid-like structure to display patient counts for different diseases, with 'clinical' highlighted in the top right.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
13
The slide uses a timeline-based layout to communicate clinical development progress and market opportunity size.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
14
The slide uses a visual representation of an antibody structure to explain the 'sweeping' mechanism.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
15
Includes immunofluorescence microscopy images and bar charts showing tidal volume and respiratory rate metrics.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
16
The slide illustrates the neuromuscular junction mechanism and the clinical trial progression from healthy volunteers to patients with CMS and MuSK MG.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
17
The slide uses a horizontal layout of four circular icons with corresponding text blocks below, representing a portfolio segmentation.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations Loop · Quick Win Big Bet1 hit
18
The slide uses a network-like background with lines connecting various logos, suggesting a collaborative ecosystem.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
19
The slide uses a dual-section layout to separate commercial regulatory events from clinical trial data readouts and study initiations.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
20
The diagram features five values: Co-Creation, Empowerment, Excellence, Humility, and Innovation.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
21
The chart uses a horizontal bar format to represent clinical trial stages (Preclinical to Commercial) for multiple indications under four main programs (VYVGART, Efgartigimod, ARGX-117, ARGX-119).argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
22
The slide uses a process flow diagram to illustrate the clinical trial methodology.argenx SE | Investor Presentation Deck | 22 slides · argenx
Conference presentation Investor relations 1 hit
01
Slide 1
argenx SE | Results Presentation Deck | 11 slidesargenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations 1 hit
02
argenx SE | Results Presentation Deck | 11 slidesargenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations 1 hit
03
The slide uses a central Venn-like diagram of four circles to organize key company achievements and focus areas.argenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations Beat · What Is1 hit
04
The slide uses a combination of line charts for clinical data and a list for safety metrics, followed by a logo-grid of scientific journals.argenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations Beat · What Is1 hit
05
The diagram uses a clover-like circular layout to represent interconnected strategic pillars.argenx SE | Results Presentation Deck | 11 slides · argenx
Conference presentation Investor relations Beat · What Is1 hit